SIMULTANEOUSLY MONITORING OF SERUM AND URINE CYTOMEGALOVIRUS DNA IN PATIENTS UNDERWENT HEMATOPOIETIC STEM CELL TRANSPLANTATION
(Abstract release date: 05/19/16)
EHA Library. Lu Y. 06/09/16; 134798; PB1898
Dr. Ying Lu
Contributions
Contributions
Abstract
Abstract: PB1898
Type: Publication Only
Background
Hemorrhagic cystitis (HC) is one of the most common complications after hematopoietic stem cell transplantation (HSCT). Early diagnosis of HC is very important to improve the disease prognosis.
Aims
The aim of this work is to explore the significance of simultaneously monitoring serum and urine cytomegalovirus(CMV) DNA on diagnosing HC after HSCT.
Methods
57 patients were included in this study and median age was 32 years(range 10-54). 40 patients were diagnosed of acute leukemias, 6 were lymphoma, 5 were severe aplastic anemia, 4 were chronic myelocytic leukemias, 1 was myelodysplatic syndrome and 1 was multiple myeloma. Among the 57 patients, 30 patients received graft from HLA-identical relative donors, 10 patients received graft from HLA- identical unrelated donors, 10 underwent auto-HSCT and 7 underwent unrelated cord blood transplantation. Serum CMV DNA was tested weekly by real-time PCR from one week before conditioning to 100 days after HSCT. For patients with CMV viremia or lower urinary tract symptoms, urine CMV DNA was also tested.
Results
Within 100 days after transplant, 23/57 (40.35％) patients developed CMV viremia. Among the 23 patientsa, 8 developed CMV uremia. Only 2（5.88%）patients presented CMV uremia in the 34 patients with normal serum CMV DNA. All of the 10 patients with CMV uremia had complaints of lower urinary tract symptoms and were found abnormal urine routine result and CMV related HC was considered. 10 patients received anti-virus treatment and all of them obtained complete remission.
Conclusion
The incidence of CMV infection is still high during HSCT. For patients with CMV viremia, urine CMV-DNA surveillance is necessary in order to diagnose HC early and improve the disease prognosis.
Session topic: E-poster
Keyword(s): Cytomegalovirus
Type: Publication Only
Background
Hemorrhagic cystitis (HC) is one of the most common complications after hematopoietic stem cell transplantation (HSCT). Early diagnosis of HC is very important to improve the disease prognosis.
Aims
The aim of this work is to explore the significance of simultaneously monitoring serum and urine cytomegalovirus(CMV) DNA on diagnosing HC after HSCT.
Methods
57 patients were included in this study and median age was 32 years(range 10-54). 40 patients were diagnosed of acute leukemias, 6 were lymphoma, 5 were severe aplastic anemia, 4 were chronic myelocytic leukemias, 1 was myelodysplatic syndrome and 1 was multiple myeloma. Among the 57 patients, 30 patients received graft from HLA-identical relative donors, 10 patients received graft from HLA- identical unrelated donors, 10 underwent auto-HSCT and 7 underwent unrelated cord blood transplantation. Serum CMV DNA was tested weekly by real-time PCR from one week before conditioning to 100 days after HSCT. For patients with CMV viremia or lower urinary tract symptoms, urine CMV DNA was also tested.
Results
Within 100 days after transplant, 23/57 (40.35％) patients developed CMV viremia. Among the 23 patientsa, 8 developed CMV uremia. Only 2（5.88%）patients presented CMV uremia in the 34 patients with normal serum CMV DNA. All of the 10 patients with CMV uremia had complaints of lower urinary tract symptoms and were found abnormal urine routine result and CMV related HC was considered. 10 patients received anti-virus treatment and all of them obtained complete remission.
Conclusion
The incidence of CMV infection is still high during HSCT. For patients with CMV viremia, urine CMV-DNA surveillance is necessary in order to diagnose HC early and improve the disease prognosis.
Session topic: E-poster
Keyword(s): Cytomegalovirus
Abstract: PB1898
Type: Publication Only
Background
Hemorrhagic cystitis (HC) is one of the most common complications after hematopoietic stem cell transplantation (HSCT). Early diagnosis of HC is very important to improve the disease prognosis.
Aims
The aim of this work is to explore the significance of simultaneously monitoring serum and urine cytomegalovirus(CMV) DNA on diagnosing HC after HSCT.
Methods
57 patients were included in this study and median age was 32 years(range 10-54). 40 patients were diagnosed of acute leukemias, 6 were lymphoma, 5 were severe aplastic anemia, 4 were chronic myelocytic leukemias, 1 was myelodysplatic syndrome and 1 was multiple myeloma. Among the 57 patients, 30 patients received graft from HLA-identical relative donors, 10 patients received graft from HLA- identical unrelated donors, 10 underwent auto-HSCT and 7 underwent unrelated cord blood transplantation. Serum CMV DNA was tested weekly by real-time PCR from one week before conditioning to 100 days after HSCT. For patients with CMV viremia or lower urinary tract symptoms, urine CMV DNA was also tested.
Results
Within 100 days after transplant, 23/57 (40.35％) patients developed CMV viremia. Among the 23 patientsa, 8 developed CMV uremia. Only 2（5.88%）patients presented CMV uremia in the 34 patients with normal serum CMV DNA. All of the 10 patients with CMV uremia had complaints of lower urinary tract symptoms and were found abnormal urine routine result and CMV related HC was considered. 10 patients received anti-virus treatment and all of them obtained complete remission.
Conclusion
The incidence of CMV infection is still high during HSCT. For patients with CMV viremia, urine CMV-DNA surveillance is necessary in order to diagnose HC early and improve the disease prognosis.
Session topic: E-poster
Keyword(s): Cytomegalovirus
Type: Publication Only
Background
Hemorrhagic cystitis (HC) is one of the most common complications after hematopoietic stem cell transplantation (HSCT). Early diagnosis of HC is very important to improve the disease prognosis.
Aims
The aim of this work is to explore the significance of simultaneously monitoring serum and urine cytomegalovirus(CMV) DNA on diagnosing HC after HSCT.
Methods
57 patients were included in this study and median age was 32 years(range 10-54). 40 patients were diagnosed of acute leukemias, 6 were lymphoma, 5 were severe aplastic anemia, 4 were chronic myelocytic leukemias, 1 was myelodysplatic syndrome and 1 was multiple myeloma. Among the 57 patients, 30 patients received graft from HLA-identical relative donors, 10 patients received graft from HLA- identical unrelated donors, 10 underwent auto-HSCT and 7 underwent unrelated cord blood transplantation. Serum CMV DNA was tested weekly by real-time PCR from one week before conditioning to 100 days after HSCT. For patients with CMV viremia or lower urinary tract symptoms, urine CMV DNA was also tested.
Results
Within 100 days after transplant, 23/57 (40.35％) patients developed CMV viremia. Among the 23 patientsa, 8 developed CMV uremia. Only 2（5.88%）patients presented CMV uremia in the 34 patients with normal serum CMV DNA. All of the 10 patients with CMV uremia had complaints of lower urinary tract symptoms and were found abnormal urine routine result and CMV related HC was considered. 10 patients received anti-virus treatment and all of them obtained complete remission.
Conclusion
The incidence of CMV infection is still high during HSCT. For patients with CMV viremia, urine CMV-DNA surveillance is necessary in order to diagnose HC early and improve the disease prognosis.
Session topic: E-poster
Keyword(s): Cytomegalovirus
{{ help_message }}
{{filter}}